eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes
Lei Gao(China Agricultural University), Ayako Makino, Md Rahatullah Razan(University of the Pacific), Atsumi Tsuji‐Hosokawa(Tokyo Medical and Dental University), Jody Tori O. Cabrera(University of California San Diego), Sara M. Camp, Joe G. N. Garcia(Scripps Research Institute), Makiko Watanabe(The University of Texas at Austin), Jian Wang(Guangzhou Experimental Station), Francisco J. Ramírez(Scripps Research Institute), Qiuyu Zheng(University of California System), Carrie L. Kempf, Mingya Yang(Scripps Research Institute), Mathews Valuparampil Varghese(Indiana University)
Cited by 6
Related Papers
Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis
|JAMA|2013|456
Activated Protein C Mediates Novel Lung Endothelial Barrier Enhancement
|Journal of Biological Chemistry|2005|355
Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis
|Science Translational Medicine|2013|350
Urban particulate matter triggers lung inflammation via the ROS-MAPK-NF-κB signaling pathway
|Journal of Thoracic Disease|2017|266
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
|The Lancet Respiratory Medicine|2018|215